|
|
|
|
|
Dapsone: profile and news
Early leprosy treatment encouraged Feb 15, 2006 Add new comment Feb 5, 2006 The Rosacea and Wrinkle Cure Feb 7, 2006 How far has TN gone in rooting out leprosy Feb 18, 2006 The Rosacea and Wrinkle Cure Feb 7, 2006 Add new comment Feb 5, 2006 Mah achieves high rate of elemination of leprosy Jan 30, 2006 Skin-Flick Awards, Incendiary Events and Hawaiian Lepers: Books Jan 26, 2006 New antimalarial combination confirms its potential use in ... Nov 15, 2005 RI to lobby EU on fish exports Nov 28, 2005 Therapy fights drug-resistant malaria Nov 15, 2005 New Results Show the RTS,S Malaria Vaccine Candidate Protects ... Nov 15, 2005 New results show the RTS,S malaria vaccine candidate protects ... Nov 15, 2005 WHO, Swiss pharmaceutical gaint extend agreement on free ... Nov 7, 2005 Fighting Malaria Oct 24, 2005 Waiting for a Messiah!-I Oct 11, 2005 Waiting for a Messiah!-I 11 Oct 2005 Many meds don't mix with the sun Sep 21, 2005 Leap of faith Aug 16, 2005 Leprosy (Hansen's Disease) Aug 24, 2005 Other information Indication For tje treatment and management of Leprosy and Dermatitis Herpetiformis Pharmacology Dapsone is a sulfone with anti-inflammatory immunosuppressive properties as well as antibacterial and antibiotic properties. Dapsone is the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. As an anti-infective agent, it is also used for treating malaria and, recently, for Pneumocystic carinii pneumonia in AIDS patients. Dapsone is absorbed rapidly and nearly completely from the gastrointestinal tract. Dapsone is distributed throughout total body water and is present in all tissues. However, it tends to be retained in skin and muscle and especially in the liver and kidney: traces of the drug are present in these organs up to 3 weeks after therapy cessation. Mechanism Of Action Dapsone acts against bacteria and protozoa in the same way as sulphonamides, that is by inhibiting the synthesis of dihydrofolic acid through competition with para-amino-benzoate for the active site of dihydropteroate synthetase. The anti-inflammatory action of the drug is unrelated to its antibacterial action and is still not fully understood. Drug Category Leprostatic Agents; Antimalarials; Anti-inflammatory Agents; Anti-Infectives; Antimycobacterials; ATC:J04BA02 Brand Names/Synonyms 1358F; Acedapsone; Araldite Ht; Avlosulfon; Avlosulfone; Avlosulphone; Croysulfone; Croysulphone; DADPS; DDS; DSS; Dapson; Dapsone; Dapsonum; Dds, Diaphenylsulfone; Dds, Pharmaceutical; Diaminodifenilsulfona; Diaminodiphenyl Sulfone; Diaphenylsulfon; Diaphenylsulfone; Diaphenylsulphon; Diaphenylsulphone; Dimitone; Diphenasone; Diphone; Disulone; Dubronax; Dumitone; Eporal; F 1358; ICI; K509; Maloprim; Metabolite C; N, N'-Diphenyl Sulfondiamide; NSC 6091D; NSC-6091; Normet; Novophone; P, P'-Sulfonyldianiline; P,P'-Diaminodiphenyl Sulfone; P,P-Diaminodiphenyl Sulphone; P,P-Sulfonylbisbenzamine; P,P-Sulfonylbisbenzenamine; P,P-Sulphonylbisbenzamine; P,P-Sulphonylbisbenzenamine; P,P-Sulphonyldianiline; P-Aminophenyl Sulfone; Recolip; Sulfadione; Sulfanona-Mae; Sulfon-Mere; Sulfona; Sulfona-Mae; Sulfone Ucb; Sulfonyldianiline; Sulphadione; Sulphon-Mere; Sulphonyldianiline; Sumicure S; Tarimyl; Udolac; WR 448 Dosage Forms TABLET Absorption Not Available Interactions -->Interactions for Dapsone: A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/SMX). During co-administration, systemic levels of TMP and SMX were essentially unchanged. However, levels of dapsone and its metabolites increased in the presence of TMP/SMX. Systemic exposure (AUC0-12) of dapsone and N-acetyl-dapsone (NAD) were increased by about 40% and 20% respectively in presence of TMP/SMX. Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of TMP/SMX. Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with TMP/SMX. Certain concomitant medications (such as rifampin, anticonvulsants, St. Johnís wort) may increase the formation of dapsone hydroxylamine, a metabolite of dapsone associated with hemolysis. With oral dapsone treatment, folic acid antagonists such as pyrimethamine have been noted to possibly increase the likelihood of hematologic reactions. |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |